Merck & Co., Inc. (NYSE:MRK)

CAPS Rating: 4 out of 5

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.


Player Avatar joryko (99.24) Submitted: 6/12/2013 11:44:21 PM : Outperform Start Price: $47.36 MRK Score: +2.09

Long-term outperform for a steady Eddie in a strong industry.

- Incredibly strong drug pipeline
- Josh Brown's top Dow selection for the next 17 years. (cicada reference)
- 3.6% dividend
- Broad demographic shift towards more demand for their goods
- Somewhat expensive, but justified, as it is a great defensive selection

5+ year outperform as Merck looks to reinvigorate its sales with 6 quality drugs in its pipeline.

Featured Broker Partners